David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors

Anti-SARS-CoV-2 monoclonal antibodies and vaccines have shown improvement in lowering viral burden and hospitalization. However, emerging SARS-CoV-2 variants contain neutralizing antibody-escape mutations. Therefore, several reports have suggested the administration of recombinant angiotensin-conver...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfaleh, Mohamed A., Zawawi, Ayat, Al-Amri, Sawsan S., Hashem, Anwar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986284/
https://www.ncbi.nlm.nih.gov/pubmed/35380919
http://dx.doi.org/10.1080/19420862.2022.2057832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986284/
https://www.ncbi.nlm.nih.gov/pubmed/35380919
http://dx.doi.org/10.1080/19420862.2022.2057832

Ejemplares similares